Your browser doesn't support javascript.
loading
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
van Zeijl, Michiel C T; van Breeschoten, Jesper; de Wreede, Liesbeth C; Wouters, Michel W J M; Hilarius, Doranne L; Blank, Christian U; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; de Groot, Jan Willem B; Hospers, Geke A P; Kapiteijn, Ellen; Piersma, Djura; van Rijn, Rozemarijn S; Stevense-den Boer, Marion A; van der Veldt, Astrid A M; Vreugdenhil, Gerard; Boers-Sonderen, Marye J; Suijkerbuijk, Karijn P M; Haanen, John B A G; van den Eertwegh, Alfons J M.
Afiliación
  • van Zeijl MCT; Scientific Department, Dutch Institute for Clinical Auditing.
  • van Breeschoten J; Department of Medical Oncology, Leiden University Medical Centre.
  • de Wreede LC; Scientific Department, Dutch Institute for Clinical Auditing.
  • Wouters MWJM; Department of Medical Oncology, Amsterdam UMC-location VUmc, Cancer Center Amsterdam.
  • Hilarius DL; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.
  • Blank CU; Scientific Department, Dutch Institute for Clinical Auditing.
  • Aarts MJB; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.
  • van den Berkmortel FWPJ; Department of Surgical Oncology, Netherlands Cancer Institute.
  • de Groot JWB; Department of Pharmacy, Rode Kruis Ziekenhuis, Beverwijk.
  • Hospers GAP; Divisions of Medical Oncology and Molecular Oncology & Immunology, Netherlands Cancer Institute.
  • Kapiteijn E; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam.
  • Piersma D; Department of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht.
  • van Rijn RS; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Sittard-Geleen.
  • Stevense-den Boer MA; Isala Oncology Center, Isala, Zwolle.
  • van der Veldt AAM; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen.
  • Vreugdenhil G; Department of Medical Oncology, Leiden University Medical Centre.
  • Boers-Sonderen MJ; Department of Internal Medicine, Medisch Spectrum Twente, Enschede.
  • Suijkerbuijk KPM; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden.
  • Haanen JBAG; Department of Internal Medicine, Amphia Hospital, Breda.
  • van den Eertwegh AJM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, Rotterdam.
J Immunother ; 46(5): 197-204, 2023 06 01.
Article en En | MEDLINE | ID: mdl-37103470
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Melanoma Tipo de estudio: Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Melanoma Tipo de estudio: Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article